Allspring Global Investments Holdings LLC Has $1.93 Million Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Allspring Global Investments Holdings LLC reduced its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 37.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,314 shares of the life sciences company's stock after selling 26,513 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.06% of Integra LifeSciences worth $1,930,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Gladius Capital Management LP acquired a new position in Integra LifeSciences during the third quarter worth about $47,000. Covestor Ltd grew its holdings in Integra LifeSciences by 82.5% in the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company's stock valued at $78,000 after purchasing an additional 921 shares during the last quarter. International Assets Investment Management LLC purchased a new position in shares of Integra LifeSciences in the fourth quarter valued at $190,000. Empirical Asset Management LLC purchased a new stake in shares of Integra LifeSciences in the 4th quarter worth about $212,000. Finally, Panagora Asset Management Inc. purchased a new stake in shares of Integra LifeSciences in the 3rd quarter worth about $223,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

Integra LifeSciences Trading Up 1.0 %

Shares of NASDAQ IART traded up $0.30 during midday trading on Monday, hitting $28.98. The stock had a trading volume of 1,611,698 shares, compared to its average volume of 687,819. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94. Integra LifeSciences Holdings Co. has a 1-year low of $27.85 and a 1-year high of $59.10. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of 34.92, a PEG ratio of 0.86 and a beta of 1.12. The company has a fifty day moving average price of $36.55 and a 200 day moving average price of $39.03.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing analysts' consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business had revenue of $397.00 million for the quarter, compared to analyst estimates of $399.30 million. During the same period last year, the firm earned $0.94 earnings per share. The company's quarterly revenue was down .3% on a year-over-year basis. On average, analysts predict that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IART has been the topic of several recent research reports. StockNews.com downgraded shares of Integra LifeSciences from a "buy" rating to a "hold" rating in a report on Friday, April 5th. Truist Financial dropped their price target on Integra LifeSciences from $46.00 to $41.00 and set a "hold" rating for the company in a research report on Friday, March 1st. Citigroup upgraded Integra LifeSciences from a "sell" rating to a "neutral" rating and set a $38.00 price objective for the company in a research report on Wednesday, April 3rd. Finally, JMP Securities lowered their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a "market outperform" rating for the company in a report on Thursday, February 29th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, Integra LifeSciences presently has an average rating of "Hold" and an average target price of $44.89.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.